Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs Pfizer Inc — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $90.97 (market cap $12.79B), while Pfizer Inc trades at $27.75 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 12.5× iShares JPMorgan USD Emerging Markets Bond ETF's market cap, and Pfizer Inc pays a 6.14% dividend while iShares JPMorgan USD Emerging Markets Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares JPMorgan USD Emerging Markets Bond ETF for 50 Days and Pfizer Inc for 158 Days on average.
| EMB | PFE | |
|---|---|---|
Market Cap | $12.79B | $159.59B |
Volume | 8,552,536 | 30,937,010 |
Sector | Fixed Income | Health |
52-Week High | $97.74 | $29.02 |
52-Week Low | $90.14 | $23.67 |
Typical Hold Time | 50 Days | 158 Days |
Enterprise Value | — | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB trades at $90.78, down 0.19% with a bearish technical signal from moving averages. The stock shows mixed momentum with RSI indicators suggesting potential oversold conditions at lower timeframes. Recent corporate actions include scheduled dividend payments through late 2026, though key valuation and profitability metrics remain unavailable for analysis.
The outlook remains cautious with technical indicators favoring bearish momentum. Investment appeal may center on future dividend income given the lack of current fundamental data. Primary risks include market volatility and the absence of transparent financial metrics for proper valuation assessment.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
